Jefferies reiterates Eli Lilly stock rating on GLP-1 data By Investing.com

Key: Eli Lilly reiterated 2026 revenue guidance of $80–$83B and reported LTM revenue up 45% to $65.18B, supported by strong weekly GLP-1 prescription trends (oral Wegovy ~81,200; Zepbound 27,400; Mounjaro 40,600; injectable Wegovy 19,300; Ozempic 23,300). Jefferies reiterated a Buy with a $1,300 PT and models orforglipron at ~$2B revenue in 2026 (vs $1.65B consensus); Lilly plans a $3B China investment and has a PDUFA for orforglipron on April 10, 2026, while CMS BALANCE timing (Medicaid May 2026, Medicare July 2026) improves coverage outlook; Brazil supply issues are a noted downside.

Analysis

Large-cap pharma with a new oral incretin entrant is reshaping share dynamics: incumbents with injectable-dominant franchises face two-way pressure — accelerated patient conversion to orals plus faster payer negotiation leverage that can compress realized prices. Manufacturing footprint and regional production control will become a durable differentiator; firms that can shorten lead times and localize supply will both protect launch curves and extract higher net pricing in markets sensitive to availability.

The immediate margin upside from a successful oral launch is vulnerable to three non-linear risks: a class safety signal that forces label changes, rapid payer formulary concessions that blunt list-to-net spreads, and execution glitches in scaling manufacturing outside core geographies. All three risks are observable on timelines from weeks (safety reports) to quarters (payer contracting) to multi-year (capacity buildouts), so sizing and liquidity around those windows matters.

Consensus appears to underweight the knock-on winners — CDMOs, specialty distributors in emerging markets, and regional API suppliers — while overestimating straightforward cannibalization of incumbent products. That creates cheap asymmetric trades: long optionality on the successful oral roll-out and manufacturing moat, paired with short tail-risk protection against rapid net-price erosion. Use tranche sizing that reflects the staged nature of regulatory, payer, and capacity catalysts rather than one-time binary bets.

Key Decisions for Investors

• Long LLY via a 9–12 month call spread (buy ATM call, sell near-term higher strike) sized at 2–4% of portfolio; hedge with 8–12% notional in puts. Rationale: captures upside from continued market share gains and China manufacturing optionality while capping premium spend. Target 2.5–3x upside vs max loss; close on clear negative safety signal or on material payer net-price concession.
• Relative-value pair: long LLY / short NVO, equal-dollar, horizon 6–18 months. Thesis: LLY’s oral + localized capacity optionality should outpace incumbents on a relative basis. Position stop if the pair moves against you by 8–10% on a relative basis; target 15–25% relative outperformance.
• Long CDMO exposure (example: CTLT) via 12–24 month calls or outright equity (size 1–2% portfolio). Rationale: tightening manufacturing demand and onshoring/emerging-market capacity builds favor contract manufacturers; payoff if multiple capacity-constrained quarters emerge. Risk: capex cycle oversupply; cap at 20% of notional if negative revision to demand appears.
• Tactical hedges: buy short-dated protective puts on core long positions ahead of anticipated regulatory/payer-related news flow (small size, 0.5–1% portfolio) to cap downside from binary adverse outcomes while keeping upside participation.